{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T13:23:25Z","timestamp":1777987405939,"version":"3.51.4"},"reference-count":40,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Pharmacodynamic (PD) studies with triazoles in the neutropenic murine disseminated candidiasis model have been performed extensively for\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Candida albicans<\/jats:named-content>\n            . They have consistently shown that the pharmacodynamic index most closely correlated with efficacy is the ratio of the 24-h area under the concentration-time curve (AUC) to the MIC, and a target 24-h free-drug AUC\/MIC ratio near 25 is associated with 50% of maximal microbiologic efficacy. We utilized this model to investigate the pharmacodynamics of isavuconazole. Isavuconazole pharmacokinetics were linear over the dose range studied. Oral-gastric doses of 640, 160, 40, and 10 mg of prodrug\/kg of body weight produced peak levels of 0.51 to 25.4 mg\/liter, an elimination half-life of 1 to 5 h, and an AUC from 0 h to infinity (AUC\n            <jats:sub>0-\u221e<\/jats:sub>\n            ) of 0.9 to 287 mg \u00b7 h\/liter. The AUC\/MIC ratio was the pharmacodynamic index that correlated best with efficacy (\n            <jats:sub>R<\/jats:sub>\n            <jats:sup>2<\/jats:sup>\n            , 0.84). Pharmacodynamic target studies were performed using 4\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">C. albicans<\/jats:named-content>\n            isolates with both a 24-h and a 96-h treatment duration. The strains were chosen to include previously characterized fluconazole-resistant strains. The mean 50% effective doses (ED\n            <jats:sub>50<\/jats:sub>\n            ) (expressed in mg\/kg of body weight\/12 h) and associated 24-h free-drug AUC\/MIC ratios were 89.3 \u00b1 46.7 and 67.7 \u00b1 35 for the 24-h treatment and 59.6 \u00b1 22 and 33.3 \u00b1 25.5 for the 96-h treatment. These differences were not statistically significant. Pharmacodynamic targets for two non-\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">albicans Candida<\/jats:named-content>\n            species were also explored. The mean ED\n            <jats:sub>50<\/jats:sub>\n            (expressed in mg\/kg\/12 h) and associated 24-h free-drug AUC\/MIC ratios were 31.2 and 6.2 for\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Candida tropicalis<\/jats:named-content>\n            (\n            <jats:italic>n<\/jats:italic>\n            = 1) and 50.5 and 1.6 for\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Candida glabrata<\/jats:named-content>\n            (\n            <jats:italic>n<\/jats:italic>\n            = 2). These PD targets were significantly different from\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">C. albicans<\/jats:named-content>\n            targets (\n            <jats:italic>P<\/jats:italic>\n            , 0.04). Isavuconazole PD targets for\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">C. albicans<\/jats:named-content>\n            are similar to those observed in this model with other triazoles. However, the PD targets for non-\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">albicans Candida<\/jats:named-content>\n            species were more than 10-fold lower than those for\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">C. albicans<\/jats:named-content>\n            (\n            <jats:italic>P<\/jats:italic>\n            , 0.04). This difference is similar to the species-specific PD relationships for the echinocandins. The lower PD targets for these species in this model will be important to consider in the analysis of clinical trial data and during the development of susceptibility breakpoints.\n          <\/jats:p>","DOI":"10.1128\/aac.01354-13","type":"journal-article","created":{"date-parts":[[2013,9,4]],"date-time":"2013-09-04T04:42:13Z","timestamp":1378269733000},"page":"5642-5648","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":60,"title":["Isavuconazole Pharmacodynamic Target Determination for Candida Species in an\n            <i>In Vivo<\/i>\n            Murine Disseminated Candidiasis Model"],"prefix":"10.1128","volume":"57","author":[{"given":"Alexander J.","family":"Lepak","sequence":"first","affiliation":[{"name":"University of Wisconsin, Madison, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Marchillo","sequence":"additional","affiliation":[{"name":"University of Wisconsin, Madison, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"VanHecker","sequence":"additional","affiliation":[{"name":"University of Wisconsin, Madison, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Diekema","sequence":"additional","affiliation":[{"name":"University of Iowa, Iowa City, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Andes","sequence":"additional","affiliation":[{"name":"University of Wisconsin, Madison, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00029-06"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/421946"},{"key":"e_1_3_2_4_2","first-page":"S37","article-title":"Treatment of candidiasis: a perspective on recent advances and future challenges","volume":"1","author":"Todeschini GT","year":"1997","unstructured":"TodeschiniGT. 1997. Treatment of candidiasis: a perspective on recent advances and future challenges. Int. J. Infect. Dis. 1(Suppl):S37\u2013S41.","journal-title":"Int. J. Infect. Dis."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-006-0159-2"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/378745"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.4.1179-1186.2003"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/510079"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/596757"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-010-9324-3"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01217-06"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01512-07"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.1.286-293.2006"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.1.279-285.2006"},{"key":"e_1_3_2_16_2","volume-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2008","unstructured":"Clinical and Laboratory Standards Institute (CLSI). 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 3rd ed. CLSI document M27\u2013A3. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"3"},{"key":"e_1_3_2_17_2","volume-title":"Guide for the care and use of laboratory animals","author":"National Research Council Committee on the Care and Use of Laboratory Animals, Institute of Laboratory Animal Resources, and Commission on Life Sciences","year":"1996","unstructured":"National Research Council Committee on the Care and Use of Laboratory Animals, Institute of Laboratory Animal Resources, and Commission on Life Sciences. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.137-142.2004"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.10.3165-3169.2003"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.4.1193-1199.2003"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.9.2116"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01584-09"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01061-07"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00478-08"},{"key":"e_1_3_2_25_2","first-page":"111","article-title":"Use of an animal model of disseminated candidiasis in the evaluation of antifungal therapy","volume":"118","author":"Andes D","year":"2005","unstructured":"AndesD. 2005. Use of an animal model of disseminated candidiasis in the evaluation of antifungal therapy. Methods Mol. Med. 118:111\u2013128.","journal-title":"Methods Mol. Med."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.4.1187-1192.2003"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/518137"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2009.02913.x"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01601-08"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.7.1917-1920.2000"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.5.1105"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00116-08"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3171-3177.2005"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.10.2715-2718.2000"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00474-06"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/24.2.235"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00296-07"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-004-1128-2"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01430-10"},{"key":"e_1_3_2_40_2","volume-title":"Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology","author":"Desai A","year":"2012","unstructured":"DesaiAZadeikisNPearlmanHKowalskiDTownsendR. 2012. Effect of multiple doses of isavuconazole on the pharmacokinetics of CYP3A4 substrate midazolam in healthy volunteers, abstr A-1936. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.06.003"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01354-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01354-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:32:53Z","timestamp":1645482773000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01354-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1128\/AAC.01354-13"],"URL":"https:\/\/doi.org\/10.1128\/aac.01354-13","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"2013-06-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-08-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-10-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}